Aerie Pharmaceuticals Incの評価平均
Aerie Pharmaceuticals Incの評価平均は何ですか。
Aerie Pharmaceuticals Incの評価平均は1.43です。
評価平均の定義は何ですか。
Recommendation meanは、株式のアナリストの格付けの平均値で、1.0（強い買い）から5.0（強い売り）の範囲です。
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
NASDAQのセクタHealth Careにおける評価平均の企業と比べるAerie Pharmaceuticals Inc
Aerie Pharmaceuticals Incは何をしますか。
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Incと類似の評価平均
- LHC Incの評価平均は1.42です。
- Imax Corpの評価平均は1.42です。
- TAL Educationの評価平均は1.42です。
- Coherent Corpの評価平均は1.42です。
- Canadian Natural Resourcesの評価平均は1.42です。
- Semtechの評価平均は1.42です。
- Aerie Pharmaceuticals Incの評価平均は1.43です。
- Addus HomeCareの評価平均は1.44です。
- Biolife Solutions Incの評価平均は1.44です。
- Visa Incの評価平均は1.44です。
- ServiceNow Incの評価平均は1.44です。
- Daqo New Corpの評価平均は1.44です。
- ACM Research Incの評価平均は1.44です。